SA

Sakae Asanuma

President & CEO at Taiho Ventures, LLC

San Francisco Bay Area

Investor
VC

Invests in

Stages:

Pre-seed
Seed

  • Min Investment:

    $100,000.00

  • Max Investment:

    $5,000,000.00

  • Target Investment:

    $1,500,000.00

Skills

Biotechnology
Due Diligence
Venture Capital
Investments
Corporate Development
Start-ups
Entrepreneurship
Mergers
Business Strategy
Lifesciences
Private Equity
Life Sciences
Valuation
Strategy
Commercialization
Mergers & Acquisitions
Pharmaceutical Industry
Technology Transfer

Education

Lists including Sakae

AH
AE
AF
AJ

Based in SF

3077 people

AM
AT
AS
AR

All Seed Investors

19691 people

AT
AE
AE
AL

All Pre-Seed Investors

7972 people

PS
PS
PC
PM

Pre-seed Investors in San Francisco

993 people

Investments

Anavo Therapeutics

Seed

Total Funding: $33M

Cellvie

Seed

Total Funding: $6M

Dren Bio

Series A

Total Funding: $130M

Axial Biotherapeutics

Series B

Total Funding: $86M

Orna Therapeutics

Series A

Total Funding: $320M

Theolytics

Series A

Total Funding: $7M

Storm Therapeutics

Series A

Total Funding: $69M

Work Experience

Taiho Ventures, LLC

2016

  • President & CEO

    2016

Astellas Venture Management LLC

2011 - 2016

  • President and CEO

    2012 - 2016

  • Managing Director Investment

    2011 - 2012

Yasuda Enterprise Development

1997 - 2010

  • Director

    1997 - 2010

    Identify and invest in promising biotech venture companies in the US.

Meiji Yasuda Life Insurance

1988 - 1999

  • Buyside Analyst

    1988 - 1999